PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has received new commercial health plan coverage for the ...

Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients U.S. Medicare coverage decision reflects published, peer-reviewed clinical data ...

Cancer test maker Lucid Diagnostics (NASDAQ:LUCD), majority owned by PavMed (NASDAQ:PAVM), traded ~8% lower on Wednesday after the company said that a group of medical experts will meet in September ...

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage of its ultrasensitive NeXT Personal® test for ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received confirmation that its Prospera Lung donor-derived ...

Just 48 hours after her birth in a Seattle-area hospital in 2021, Layla Babayev was undergoing surgery for a bowel obstruction. Two weeks later, she had another emergency surgery, and then developed ...

(Reuters) - Guardant Health said its blood test to detect cancer that starts in the colon or rectum got an approval from the U.S. Food and Drug Administration, with the test moving closer toward ...

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) ...

The FDA approved Foundation Medicine’s cancer gene test Thursday. CMS also proposed national coverage of the test for Medicare beneficiaries with advanced cancer. The FoundationOne CDx is an in vitro ...